Document:

License Agreement, dated January 29, 2007, Salk Institute for Biological Studies

 Exhibit 10.9 
 LICENSE AGREEMENT 
 This License Agreement (the “Agreement”) is made and entered into as of
January 29, 2007, (the “Effective Date”) by and between the Salk Institute for Biological Studies, a nonprofit public benefit corporation organized under the laws of the State of California (“Salk”), and Merrion Research I,
Ltd., a corporation organized under the laws of Ireland (“Licensee”). 
 WHEREAS, Salk is the owner of
certain Patent Rights (as hereinafter defined); 
 WHEREAS, the development of the inventions contained in the Patent
Rights was sponsored in part by the National Institutes of Health and, as a consequence, Salk is subject to obligations to the Federal Government as set forth in 35 U.S.C. §200 et seq.; 
 WHEREAS, Salk desires that the Patent Rights be developed and utilized to the fullest extent possible so that products resulting
therefrom may be available for public use and benefit; 
 WHEREAS, Salk has determined that the best method for
disseminating the Patent Rights is through the grant of an exclusive license to an entity willing to establish a program to develop therapeutic, diagnostic or research products in the Field of Use covered by such Patent Rights; 
 WHEREAS, Licensee represents that it has the intent and resources to develop and market products based upon the Patent Rights; and

 WHEREAS, The parties executed an Option Agreement, effective January 23, 2006, and pursuant to the Option
Agreement, Licensee wishes to obtain, and Salk is willing to grant, a license to the Patent Rights in the defined Field of Use, subject to the terms set forth below. 
 NOW, THEREFORE, in consideration of the above premises and the mutual covenants contained herein, the parties hereby agree as follows: 
  

 1 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

	1	DEFINITIONS. 

 1.1 The term
“Affiliate” shall mean any entity that controls, is controlled by or is under common control with Licensee, where “control” means (i) beneficial ownership of more than fifty percent (50%) of the outstanding
shares or securities of the entity, or (ii) the ability otherwise to direct or cause the direction of the management and policies of such entity. 
 1.2 The term “Commercial Sale” shall mean any sale, lease, or other transaction that transfers to an independent third party in an arms-length transaction, for value, physical possession of and
title to a Licensed Product, after which transfer the seller has no right or power to determine the purchaser’s resale price. Transfer of possession and title to an Affiliate or Sublicensee shall not constitute a Commercial Sale unless the
Affiliate or Sublicensee is an end user of the Licensed Product. 
 1.3 The term “FDA” shall mean the United States
Food and Drug Administration. 
 1.4 The term “Field of Use” shall mean all therapeutic uses of the Patent Rights in
humans and animals. 
 1.5 The term “Licensed Product” shall mean any product, the manufacture, use, importation,
sale, or offer for sale of which, in the absence of this Agreement, would infringe the Patent Rights. 
 1.6 The term
“NDA” shall mean a new drug application filed with the FDA pursuant to 21 U.S.C. Section 505 (b)(1) for marketing approval of a Licensed Product or any successor applications or procedures. Without limiting the foregoing, NDA
includes Product License Applications (PLA) and Biologics License Applications (BLA). 
 1.7 The term “NDA
Approval” shall mean receipt of such authorizations from the regulatory authorities in the U.S. (including marketing, labeling, packaging, pricing and reimbursement approvals) as are legally required before a Licensed Product may be
commercialized or sold. 
  

 2 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 1.8 The term “Net Sales” shall mean the gross amounts received by Licensee, its
Affiliates, and Sublicensees in the Commercial Sale of Licensed Product in the Territory, less the following amounts if separately stated on purchase orders, invoices, or other documents of sale: 
 (a) outbound shipping, storage, packing and insurance expenses, each as actually paid or allowed; 
 (b) amounts repaid or credited by reason of rejections, defects or returns, billing errors, recalls, or because of retroactive
price reductions; 
 (c) sales and other excise taxes, use taxes, tariffs, export license fees and duties actually paid
or allowed; and 
 (d) all trade, quantity, and cash discounts. 
 No deductions shall be made for commissions paid to individuals whether they are with independent sales agencies or regularly employed by Licensee, its Affiliates or
Sublicensees and on its payroll, or for cost of collections. Net Sales shall occur on the date of receipt of revenue for a Licensed Product. If a Licensed Product is distributed at a discounted price that is substantially lower than the customary
price charged by Licensee under similar circumstances, or distributed for non-cash consideration (whether or not at a discount), Net Sales shall be calculated based on the non-discounted price of the Licensed Product charged to an independent third
party during the same reporting period or, in the absence of such sales, on the fair market value of the Licensed Product. 
 Net Sales shall include the
fair market value of any non-cash consideration received by Licensee, its Affiliates or Sublicensees for the sale, lease, or transfer of Licensed Products. Licensed Product sold by Licensee to its Affiliates shall not be included in the calculation
of Net Sales hereunder; provided that, any subsequent sale or revenue generating activity of such Affiliate shall be included in computing Net Sales. Further, Net Sales shall not include any consideration received by Licensee, its Affiliates or
Sublicensees for the sale, use or other disposition of a Licensed Product as part of a clinical trial prior to the receipt of all regulatory approvals required to commence Commercial Sale of the Licensed Product. 
  

 3 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 If a Licensed Product is sold in combination with one or more other active products or components that is not a Licensed
Product (a “Combination Product”), the portion of “Net Sales” attributable to the Licensed Product will be calculated by multiplying actual Net Sales for such Combination Product by the fraction A/(A+B) where A is the
gross invoice price of the Licensed Product if sold separately, and B is the total gross invoice price of any other active components, or devices, in the combination if sold separately, in each case during the applicable reporting period or, if
sales of both the Licensed Product and the other product(s) did not occur in such period, then in the most recent royalty reporting period in which sales of both occurred provided that the last such sale of the Licensed Product and the other
product(s) is no more than six (6) months prior to the date the relevant calculation is to be made under this paragraph. In the event that such gross invoice price cannot be determined for both the Licensed Product and all other products
included in the Combination Product or the date on which the Licensed Product and such other products were both last sold was more than six (6) months before the date on which the relevant calculation is to be made, Net Sales for the purposes
of determining royalty payments shall be calculated by multiplying the Net Sales of the Licensed Product by the fraction C/(C+D) where C is the standard fully absorbed cost of the Licensed Product and D is the sum of the standard fully absorbed
costs of the other active elements or components included in the Combination Product, such costs being calculated in accordance with generally accepted accounting principles. 
 1.9 The term “Patent Costs” shall mean out-of-pocket expenses incurred by Salk for the Patent Rights in connection with the
preparation, filing, prosecution, and maintenance of patent applications and patents included therein, including the reasonable fees and expenses of attorneys and patent agents, filing fees and maintenance fees, but excluding costs associated with
any patent infringement actions. 
 1.10 The term “Patent Rights” shall mean the inventions claimed in the patents
and patent applications described below: 
 (a) Patent applications listed in Exhibit A and patents issuing therefrom.

 (b) Patents listed in Exhibit A. 
 (c) Divisional applications, provisional applications, and continuation applications that claim the benefit of priority to any of
the patents described in (a) or (b) or patent applications described in (a) or (b) and patents issuing therefrom. 
  

 4 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 (d) Continuation-in-part applications only to the extent the claimed inventions
are supported by the patents described in (a) or (b) or patent applications described in (a) or (b) and patents issuing therefrom. 
 (e) Reissue patents, extensions (including extensions under the United States Patent Term Restoration Act), renewals, substitutions and additions thereof, and reexamination patents related to patents described
in (a), (b), (c) and (d). 
 (f) Any and all foreign counterparts of the patent applications and patents described
in (a), (b), (c), (d) and (e). 
 1.11 The term “Phase I Clinical Trial” shall mean a human clinical trial in
any country intended to obtain data regarding safety and pharmacokinetics of a Licensed Product that would satisfy the requirements of United States Code of Federal Regulations 21 CFR 312.21(a), or other comparable regulation imposed by the FDA.

 1.12 The term “Phase II Clinical Trial” shall mean a human clinical trial in any country that is intended to
initially evaluate the safety, dose range and efficacy of a Licensed Product for a particular indication or indications in human subjects with the disease or indication under study or that would otherwise satisfy the requirements of United States
Code of Federal Regulations 21 CFR 312.21(b), or other comparable regulation imposed by the FDA, and that is not a Phase III Clinical Trial. 
 1.13 The term “Phase III Clinical Trial” shall mean a pivotal human clinical trial in any country the results of which could be used to establish statistical safety and efficacy of a Licensed Product as a basis for a
NDA or that would otherwise satisfy the requirements of United States Code of Federal Regulations 21 CFR 312.21(c), or other comparable regulation imposed by the FDA. 
 1.14 The term “Royalty Period” shall mean that period beginning on the date of the first Commercial Sale of a Licensed Product by Licensee, its Affiliates, or Sublicensees, and ending on the
expiration of the Patent Rights. 
 1.15 The term “Sublicensee” shall mean any non-Affiliate who sublicenses any of
the rights granted Licensee under Section 2. 
  

 5 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 1.16 The term “Sublicensing Revenue” shall mean all upfront, license, and
technology access fees, product milestone payments (whether research, preclinical or developmental), and other remuneration, however characterized (except for direct reimbursement of research or development expenditures actually incurred), received
by Licensee under a sublicense or other agreement with a Third Party for the use of the Patent Rights or the transfer or use of Licensed Products by a Third Party. Any non-cash consideration received by Licensee from Sublicensees shall be valued at
its fair market value as of the date of receipt. Sublicensing Revenue shall include any premiums paid on equity investment. The following payments received from Sublicensees shall not be considered Sublicensing Revenue: royalties paid for Net Sales
of Licensed Products, sales of equity to Sublicensees for fair market value, reimbursement of patent costs, and money loaned to Licensee at or above the then-current prime rate. If Licensee grants a sublicense to Patent Rights together with the
grant of other intellectual property owned or controlled by Licensee, Licensee shall act in good faith to allocate an appropriate portion of the aggregate consideration to the Patent Rights, and only such portion allocated to the Patent Rights shall
be treated as Sublicensing Revenue. 
 1.17 The term “Territory” shall mean the United States. 
 1.18 The term “Third Party” shall mean persons or entities other than Licensee, Salk and their respective Affiliates. 

 

	2	GRANT OF RIGHTS. 

 2.1 Patent Rights. Salk hereby grants to Licensee subject to the terms and conditions hereof an exclusive license to the Patent Rights in the Field of Use, to develop, have developed, to make, have made, to
use, have used, to import, have imported, to offer for sale, sell and have sold and otherwise commercialize any Licensed Product throughout the Territory. 
 2.2 Sublicenses. 
 (a) Licensee shall have the right to grant sublicenses of
any of the rights, privileges and licenses granted hereunder consistent with this Agreement. Licensee agrees that any sublicenses granted by it shall be subject to the terms and conditions of this Agreement, which shall be binding upon the
Sublicensee. Licensee is responsible for timely enforcement of sublicense agreements. Failure to 

  

 6 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
enforce such sublicenses will be considered a material breach. Sublicensees shall not further grant sublicenses without Salk’s prior written approval,
such approval not to be unreasonably denied. No sublicense agreement shall contain any provision that would cause it to extend beyond the term of this Agreement. Licensee further agrees to deliver to Salk for informational purposes a true and
correct copy of each sublicense granted by Licensee, and any modification or termination thereof, within thirty (30) days after execution, each modification, or termination. Failure to provide such copy will be considered a material breach of
this Agreement. Upon termination of this Agreement for any reason, all sublicenses shall survive to the extent provided in the sublicense provided (i) the sublicense contains milestone payments and royalties greater than or equal to those
included in this Agreement; (ii) the sublicensee is current on its obligations under the sublicense agreement and (iii) the sublicensee agrees to pay Salk Sublicensing Revenue due under Section 3.5, and a prorata share (based on the
number of sublicensees) of the future annual maintenance fees due under Section 3.2 and Patent Costs due under Section 7.2b. Licensee agrees to assign all such sublicenses to Salk. All sublicenses not meeting the above criteria shall
survive for a period of ninety (90) days after termination with Salk standing in the place of License. During this ninety (90) day period, Salk agrees to negotiate in good faith and execute an updated agreement with the affected
sublicensees. If no new license is completed within the ninety (90) day period, the sublicense will terminate. All payments then or thereafter due to Licensee from each surviving sublicense shall become owed directly to Salk. 
 (b) If, after the first anniversary of the Effective Date, Salk identifies a third party that has a bona fide interest in
developing and commercializing a Licensed Product, and if (i) Licensee is unable or unwilling to develop or commercialize that Licensed Product, and (ii) such Licensed Product would not compete with any Licensed Product then part of an
active research, development or commercialization program of Licensee, its Affiliates, or Sublicensees, then Licensee will, at Salk’s request, negotiate in good faith a sublicense on commercially reasonable terms with such third party for the
development and commercialization of such Licensed Product. 
 2.3 Government Rights. Licensee acknowledges that the U.S. federal
government retains a royalty-free, non-exclusive, non-transferable license to practice any government-funded invention in the Patent Rights, as set forth in 35 U.S.C. §§ 201-211 and the regulations promulgated thereunder, as amended,
or any successor statutes or regulations. 
  

 7 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 2.4 Retained Rights. Under the license granted herein, Salk reserves the right to use for research
purposes including sponsored research and collaborations, as long as the other party to the sponsored research or collaboration does not obtain rights to the Patent Rights which have already been granted exclusively under this Agreement, and the
right, upon written notice to Licensee, to allow other nonprofit or academic institutions to use for research purposes, any Patent Rights licensed hereunder, without Salk or such other institutions being obligated to pay Licensee royalties or other
compensation. Such activity shall not constitute infringement for purposes hereof. 
 2.5 No Additional Rights. 
 (a) Nothing in this Agreement shall be construed to confer any rights upon Licensee by implication, estoppel, or otherwise as to
any technology or patent rights of Salk or any other entity other than the Patent Rights, regardless of whether such technology or patent rights shall be dominant or subordinate to any Patent Rights. 
 (b) A license in any other field of use shall be the subject of a separate agreement and shall require Licensee’s submission
of evidence, satisfactory to Salk, demonstrating Licensee’s willingness and ability to develop and commercialize in such other field of use. 
 2.6 Technology Transfer. Promptly upon request by Licensee, Salk shall take all such actions as may be reasonably requested to transfer to Licensee the ability to use and practice the Patent Rights in connection with the development,
manufacture, marketing, sale and commercialization of Licensed Products. Without limiting the generality of the foregoing, Salk shall, upon request, provide Licensee with copies of or access to any available data and analytical methods relating to
the Patent Rights, and lists of suppliers of relevant materials. 
  

	3	PAYMENTS. 

 3.1 License Fee.
As partial consideration for the rights granted to Licensee under this Agreement, and payable within fifteen (15) days of execution of this Agreement, Licensee shall pay to Salk the [***] owed on a [***] nonrefundable license fee. Licensee
represents that the execution and delivery of this Agreement and the payment of the license fee have been duly and validly authorized by 

  

 8 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
all necessary corporate action by Licensee. An option fee of [***] was paid by Licensee on February 14, 2006, which is hereby credited against the
license fee. 
 3.2 Annual Maintenance Fees. Licensee agrees to pay to Salk the sum of [***] per year (the “Maintenance
Fee”), within thirty (30) days of the initiation of a Phase II Clinical Trial and each anniversary thereafter, provided that a Phase I Clinical Trial is initiated by the first anniversary of the Effective Date. If a Phase I Clinical Trial
is not initiated prior to the first anniversary of the Effective Date then the Maintenance Fee will be payable within thirty (30) days of the first anniversary of the Effective Date and each anniversary thereafter. The obligation to pay
Maintenance Fees will terminate upon the filing of an NDA. The Maintenance Fee is non-refundable and not subject to proration. 
 3.3
Milestone Payments. Licensee shall provide Salk with written notice within thirty (30) days of each achievement by Licensee or its Affiliates of each of the milestone events set forth below. Within ten (10) days after delivering each
such notice, Licensee shall pay to Salk the amounts set forth below: 
  

			
	 Milestone
	  	Amount
		
	Initiation of Phase II Clinical Study with respect to the first Licensed Product (as demonstrated by dosing of the first subject)	  	
 [***]

		
	Initiation of Phase III Clinical Study with respect to the first Licensed Product (as demonstrated by dosing of the first subject)	  	
 [***]

		
	Submission and acceptance of an NDA to the FDA or foreign equivalent with respect to the first Licensed Product	  	
 [***]

		
	Approval of an NDA by the FDA or foreign equivalent with respect to first Licensed Product	  	[***]
		
	Filing of subsequent NDA with the FDA	  	[***]
		
	Approval of subsequent NDA by the FDA	  	[***]

  

 9 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 For the avoidance of doubt, for a particular Licensed Product, written notice and a payment is required the first time
each milestone is achieved, but no additional written notice or payment is due to the extent that for the same Licensed Product a milestone is achieved again for the same indication. Any modifications of a Licensed Product are considered distinct
Licensed Products, other than modifications which are limited to changes in the formulation of a Licensed Product. Also for the avoidance of doubt, a different indication must be a distinct and different disease state, and not a subset of the same
disease or a label extension (e.g., secondary progressive multiple sclerosis is the same disease state, and therefore the same indication, as relapsing remitting multiple sclerosis). 
 Failure to make any milestone payment when due is considered a material breach of this Agreement and cause for termination under Section 9.2(b), subject to the cure period specified therein. 
 3.4 Royalty Payments. 
 (a) (a) Running Royalties. Licensee shall pay to Salk during the Royalty Period a royalty of [***] on Net Sales of Licensed Products sold by Licensee, its Affiliates or Sublicensees. Royalty payments shall be made in accordance with
Section 8. Subject to Section 1.8, on sales of Licensed Products by Licensee to Sublicensees or on sales made in other than an arm’s-length transaction, the value of the Net Sales attributed under this Article 3 to such a transaction
shall be that which would have been received in an arm’s-length transaction, based on sales of like quantity and quality products on or about the time of such transaction. 
 (b) Minimum Annual Royalties. Licensee shall pay to Salk a minimum royalty payment of [***] annually during the Royalty Period,
beginning on the one year anniversary date of the first Commercial Sale of a Licensed Product. This minimum annual royalty will be credited against the royalties due under Sections 3.4(a) for the immediately prior twelve month period for which the
minimum royalty payment is to be made on a dollar-for-dollar basis up to the full [***] paid for such twelve month period, and will be paid within thirty (30) days of each such anniversary. A minimum annual royalty payment made in one twelve
month period is not creditable against royalties accruing in a different twelve month period. 
 3.5 Other Payments. Licensee shall
pay to Salk within thirty (30) days of Licensee’s receipt, a share of Sublicensing Revenue, in an amount equal to [***] of Sublicensing Revenue if the sublicense is granted prior to initiation of a Phase II clinical trial (as demonstrated
by dosing of the first 

  

 10 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
patient), for a Licensed Product, and [***] of Sublicensing Revenue for Licensed Products if the sublicense is granted anytime after the initiation of a
Phase II clinical trial. 
 3.6 After the expiration of the Royalty Period, Licensee shall have no further obligation to pay royalties
in connection with sales of Licensed Products and the licenses granted hereunder shall be fully paid-up. 
  

	4	OWNERSHIP OF INTELLECTUAL PROPERTY. 

 Licensee (for itself, its Affiliates and Sublicensees) acknowledges and agrees that Salk is and shall remain (as to Licensee) the owner of the Patent
Rights, subject to the rights of the Federal Government as set forth in 35 U.S.C. §200 et seq., and that Licensee (including its Affiliates and Sublicensees) has no rights in or to the Patent Rights other than the rights specifically granted
herein. 
  

	5	WARRANTIES AND DISCLAIMERS. 

 5.1 Warranty Disclaimer. Nothing in this Agreement is or shall be construed as: 
 (a) a warranty or representation by Salk as to the validity or scope of any Patent Rights; 
 (b) a
warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents, copyrights and other rights of third parties; 
 (c) an obligation to bring or prosecute actions or suits against third parties for infringement, except to the extent and in the
circumstances described in Section 7.3; or 
 (d) a grant by implication, estoppel, or otherwise of any licenses
under patent applications or patents of Salk or other persons other than as provided in Section 2 hereof. 
 5.2 Representations and
Warranties by Salk. Salk represents and warrants that as of the Effective Date: (a) it is the sole owner of the Patent Rights and has the right to grant rights to the Patent 

  

 11 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
Rights as set forth in this Agreement; (b) it has not transferred any interest in the Patent Rights which may be inconsistent with the rights granted
hereunder; (c) it has not received any notice or claim alleging that any of the Patent Rights are invalid or infringe on the rights of any third party; (d) it is not aware of any infringement of the Patent Rights by a third party;
(e) it has prosecuted all patent applications within the Patent Rights in good faith and has no reason to believe that any patent or claim within the Patent Rights is invalid or would be held to be unenforceable by a court of competent
jurisdiction; and (f) no litigation is pending and no claim has been made against Salk or, to the knowledge of Salk, is threatened, which may affect the rights of Licensee hereunder. 
 5.3 Mutual Representations and Warranties. Each party represents and warrants to the other that (i) it has the legal right and power to enter
into this Agreement and to perform fully its obligations hereunder, (ii) this Agreement and the signatories hereto have been duly authorized, (iii) this Agreement is a valid and binding agreement of such party, enforceable in accordance
with its terms, (iv) this Agreement does not violate the terms of any other contract to which such party is a party, and (v) in exercising its rights and fulfilling its obligations under this Agreement, it will fully comply with the
requirements of any and all applicable laws, regulations, rules, and orders of any governmental body. 
 5.4 No Warranty. EXCEPT AS
EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION AND EXTENDS NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES AS TO TITLE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 5.5 Disclaimer of Liability. Subject to Sections 6.2 and 6.3, in no event shall either party be liable to the other party for any incidental,
special or consequential damages arising from or relating to the subject matter of this Agreement or its breach. 
  

	6	INDEMNIFICATION AND INSURANCE. 

 6.1 Indemnification by Licensee. Licensee agrees to indemnify, hold harmless and defend Salk, its trustees, officers, employees and agents, and the inventors (the “Salk Entities”) of the patents and
patent applications included in the Patent Rights against any and all liability and/or damages with respect to any claims, suits, demands, judgments or causes of action asserted by third parties arising out 

  

 12 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
of (a) the development, manufacture, storage, sale or other distribution, or any other use of Licensed Products or Patent Rights, or exercise of other
rights granted hereunder, by Licensee, its Affiliates or Sublicensees, distributors, agents or representatives; (b) the use by end-users and other third parties of Licensed Products or Patent Rights; and/or (c) any representation, warranty
or statement by Licensee or its Affiliates, Sublicensees, distributors, agents or representatives, concerning Salk, or the Patent Rights, except to the extent such liabilities and/or damages are the result of the Salk Entities’ breach of this
Agreement, gross negligence or willful misconduct. If a Salk Entity intends to claim indemnification under this Section, it shall promptly notify Licensee and Licensee shall assume the defense and shall control the defense or disposition of the
claim, at Licensee’s sole expense by counsel selected by Licensee. No settlement, consent judgment or other voluntary final disposition may be entered into that admits fault, wrongdoing or damages without the prior written consent of Salk,
which consent shall not be unreasonably withheld or delayed. Salk shall cooperate fully with Licensee and its legal representatives in the investigation and defense of any matter giving rise to a claim for indemnification hereunder, at
Licensee’s expense. 
 6.2 Insurance. 
 (a) Subject to Section 6.2(c), Licensee shall maintain, during the Term (as defined below), comprehensive general liability
insurance, including products liability insurance, with reputable and financially secure insurance carriers to cover the activities of Licensee, its Affiliates and Sublicensees. Such insurance shall include Salk as a named insured, shall require
prior notice to Salk before cancellation, shall be written to cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement and should be placed with carriers with ratings of at least A- as rated by A.M.
Best. Such insurance shall have a minimum limit of one million dollars ($1,000,000.00) per specific occurrence and a minimum limit of one million dollars ($1,000,000.00) for aggregate liability insurance; provided, however, that when Licensee or its
Affiliates or Sublicensees receives NDA Approval, such coverage shall be increased to a minimum limit of five million dollars ($5,000,000) per specific occurrence and a minimum limit of ten million dollars ($10,000,000) for aggregate liability
insurance. The minimum amounts of insurance coverage required shall not be construed to create a limit of Licensee’s liability with respect to its indemnification under this Agreement. 
 (b) Within ninety (90) days of the Effective Date of this Agreement, Licensee shall furnish a Certificate of Insurance
evidencing primary coverage and additional insured requirements and 

  

 13 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
provide Salk with copies of subsequent annual Certificates of Insurance. Licensee shall provide Salk with written notice at least fifteen (15) days
prior to the cancellation, non-renewal or material change in such insurance. It is the intention of the parties hereto that Licensee shall, throughout the term of this Agreement, continuously and without interruption, maintain in force the required
insurance coverages set forth in this Section. Failure of Licensee to comply with this requirement shall be considered a material breach of the Agreement. 
 (c) If Licensee or a Sublicensee elects to self-insure all or part of the limits described above (including deductibles or retentions that are in excess of $250,000 annual aggregate) such self-insurance program
must be acceptable to Salk at its sole reasonable discretion. 
 (d) Licensee shall maintain commercial general
liability insurance beyond the expiration or termination of this Agreement during: (i) any period that any product, process, or service, relating to, or developed pursuant to, this Agreement is being commercially distributed or sold by
Licensee, a Sublicensee, Affiliate or agent of Licensee; and (ii) thereafter for a period of three (3) years. 
  

	7	PROSECUTION AND MAINTENANCE OF PATENT RIGHTS. 

 7.1 Prosecution and Maintenance. 
 (a) Within thirty (30) days after the Effective Date, Salk shall disclose to Licensee copies of complete file histories of the Patent Rights and all other relevant documentation and information related
thereto. Salk shall have full control over prosecution and maintenance of the patent applications and patents contained in the Patent Rights. Salk will keep Licensee advised of the status of patent prosecution by providing Licensee with copies of
official communications about the patent applications and patents contained in the Patent Rights and provide Licensee with an opportunity to review and comment reasonably before the filing of such patent prosecution documents Notwithstanding
Licensee’s obligations of payment in Section 7.2 hereof, Salk shall select all outside counsel for prosecution of the Patent Rights and such counsel shall represent Salk in such prosecution. Upon Licensee’s reasonable request, Salk
shall apply for an extension of the term of any patent in the Patent Rights if appropriate under the US Drug Price Competition and Patent Term Restoration Act. Salk shall not abandon the prosecution of any patent application or the maintenance of
any patent in the Patent Rights without first notifying Licensee in writing at least sixty (60) days prior to taking any action to 

  

 14 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
abandon such Patent Rights, detailing the reason therefore, and providing Licensee with the opportunity to assume responsibility for the prosecution or
maintenance of such patent(s). 
 (b) Licensee shall notify Salk as soon as reasonably possible of a change in its
entity status under 37 C.F.R. section 1.27. Licensee’s entity status may change due to a change in the number of its employees or if any rights under Patent Rights have been transferred to or released from an affiliate, collaborator or
sublicensee. 
 7.2 Patent Costs. 
 (a) Upon execution of this Agreement, Licensee shall pay to Salk [***] as reimbursement for Patent Costs incurred through the Effective Date with respect to the U.S. patents and patent applications within the
Patent Rights. 
 (b) Licensee shall reimburse Salk for all Patent Costs incurred after the Effective Date. Salk will
provide an invoice to Licensee for Patent Costs at least semiannually, and Licensee shall reimburse Salk for such Patent Costs within thirty (30) days after delivery of any such invoice. Pursuant to Section 8.5, late payments shall be
subject to a charge of one and one-half percent (1.5%) per month compounded or the highest amount allowed by law, whichever is lower. The payment of such late charges shall not prevent Salk from exercising any other rights it may have as a
consequence of the lateness of any payment. Failure to pay within thirty (30) days after receipt of invoice will be considered a material breach of this Agreement. 
 (c) Licensee may elect to surrender its Patent Rights in any country by providing to Salk written notice of such intent at least
forty-five (45) days prior to such surrender. Such notice may be provided by mail, electronic mail or facsimile directly to Salk Patent Counsel. Such notice shall not relieve Licensee from responsibility to reimburse Salk for patent-related
expenses incurred prior to the expiration of the forty-five (45) day notice period (or such longer period specified in Licensee’s notice). In the event Licensee elects to surrender any Patent Rights, such patent application or patent shall
be excluded from the definition of the Patent Rights and from the scope of the license granted under this Agreement, and all rights relating thereto shall revert to Salk and may be freely licensed by Salk. 
  

 15 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 7.3 Infringement of Patent Rights. 
 (a) In the event Licensee or Salk becomes aware of any actual or potential infringement of any Patent Rights, that party shall
promptly notify the other, and shall provide the other party with any evidence available pertaining thereto, and the parties shall discuss the most appropriate action to take. Salk and Licensee will cooperate with each other to attempt to terminate
such infringement without litigation. If attempts to abate such infringement are unsuccessful, Licensee shall consult with Salk and shall consider the views of Salk regarding the advisability of any proposed action and its effect on the public
interest. Licensee shall have the primary right, but not the obligation, to take whatever steps it considers necessary or appropriate, at its own expense, to protect or enforce the Patent Rights, by counsel of its choosing, including granting the
infringer a sublicense of the Patent Rights. Salk shall cooperate with Licensee as reasonably requested, and Licensee shall reimburse Salk for any out of pocket expenses incurred in providing such assistance. 
 (b) No settlement, consent judgment or other voluntary final disposition of the action that adversely affects the rights or
interests of Salk under this Agreement, including issues of validity of the Patent Rights, may be entered into without the prior written consent of Salk, which consent shall not be unreasonably withheld. To the extent Licensee’s recoveries from
such infringement action exceed Licensee’s expenses, Licensee agrees to pay Salk an amount equal to ten percent (10%) of such excess recoveries. 
 (c) If required by law, Salk shall permit any action brought by Licensee under this Section to be brought in its name, including being joined as a party-plaintiff, provided that Licensee shall hold Salk
harmless from, and indemnify Salk against, any costs, expenses, or liability that Salk incurs in connection with such action. To the extent recoveries from such action exceed Licensee’s expenses, Licensee agrees to pay Salk an amount equal to
ten percent (10%) of such excess recoveries. 
 (d) Salk may, on its own initiative, join such action at its own
expense, it being understood that Licensee shall have the final decision-making authority with respect to any legal proceeding Licensee elects to pursue or defend. In the event recoveries exceed Salk and Licensee’s expenses, Licensee agrees to
pay Salk an amount equal to ten percent (10%) of such excess recoveries. 
 (e) In the event that Licensee elects
not to institute or prosecute any suit to enjoin or recover damages from any infringer, then Licensee shall notify Salk in writing within sixty (60) days of determining that it shall neither enforce the Patent Rights nor engage in bona fide
negotiations to abate 

  

 16 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
the infringement or sublicense the infringer. Following such notification, then Salk alone may, in its sole discretion and at its expense, initiate and
conduct an infringement action, and any settlement or award which may be obtained shall be solely Salk’s. 
 7.4 Defense against
Third Party Infringement Claims. In the event any Licensed Product becomes the subject of a claim for patent or other proprietary right infringement anywhere in the world by virtue of the incorporation of the Patents Rights, the parties shall
promptly give notice to the other and meet to consider the claim and the appropriate course of action. Licensee shall have the right and responsibility to conduct the defense, by counsel of its own choice and at its own expense, of any such suit
brought against Licensee and/or Salk. In no event shall Licensee enter into any settlement, consent judgment or other voluntary final disposition of the suit which makes any admission regarding (i) wrongdoing on the part of Salk, or
(ii) the invalidity, unenforceability or absence of infringement of Patent Rights, without the prior written consent of Salk, which consent shall not be unreasonably withheld. The parties shall cooperate with each other in connection with any
such claim, suit or proceeding and shall keep each other reasonably informed of all material developments in connection with any such claim, suit or proceeding. 
 7.5 Marking. Licensee agrees to mark and to require any Affiliate or Sublicensee to mark any Licensed Products (or their containers or labels) made, sold, or otherwise distributed by it or them with any notice
of patent rights necessary under applicable law to enable the Patent Rights to be enforced to their full extent in any country where Licensed Products are made, used, sold, or offered for sale. 
  

	8	REPORTING, VERIFICATION AND PAYMENT. 

 8.1 Books and Records. Licensee agrees to keep proper records of scientific research and
books of account in accordance with generally accepted accounting practices. Such records and books shall include all information necessary for the accurate determination of royalty payments, Sublicensing Revenue, diligence obligation and milestone
achievement. Licensee agrees to deliver to Salk, within forty-five (45) days after the end of each calendar quarter (March 31st, June 30th, September 30th and December 31st)
during the Royalty Period, a report showing the information on which payments herein provided are calculated, including a breakdown of income from sales of each Licensed Product and to accompany each such report with the payment shown to be due
thereby. All amounts accrued for the 

  

 17 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
benefit of Salk shall be deemed held in trust for the benefit of Salk until payment of such amounts is made pursuant to this Agreement. Progress Reports
showing records of scientific research are to be provided in accordance with Section 12.3. All reports required hereunder shall be deemed Licensee Confidential Information pursuant to Article 10. 
 8.2 Audit. On reasonable written notice (at least ten (10) days)) and no more than once per year, Salk, at its own expense, shall have the
right to have an independent certified public accountant inspect and audit the books and records of Licensee and Affiliates during usual business hours for the sole purpose of, and only to the extent necessary for, determining the correctness of
royalty payments, Sublicensing Revenue, and milestone achievement under this Agreement. Such examination with respect to any calendar quarter, shall not take place later than three (3) years following the end of such calendar quarter. Such
certified public accountant shall execute a written non-disclosure agreement reasonably acceptable to Licensee. The expense of any such audit shall be borne by Salk; provided, however, that, if the audit discloses an error in excess of five percent
(5%) in favor of Licensee, then Licensee shall pay, in addition to the amount of any underpayment, the cost to Salk of the audit. 
 8.3 Foreign Payments. Royalties based on Net Sales in any foreign country shall be payable to Salk in the United States in United States Dollars. Dollar amounts shall be calculated using the foreign exchange rate, as published by the
eastern edition of The Wall Street Journal, in effect for such foreign currency on the last business day of the applicable calendar quarter for which a report is required. Where royalties are due for Net Sales in a country where, for reasons of
currency, tax or other regulations, transfer of foreign currency out of such country is prohibited, Licensee has the right to place Salk’s royalties in a bank account in such country in the name of and under the sole control of Salk; provided,
however, that the bank selected be reasonably acceptable to Salk and that Licensee inform Salk of the location, account number, amount and currency of money deposited therein. After Salk has been so notified, those monies shall be considered as
royalties duly paid to Salk and will be completely controlled by Salk. 
 8.4 Taxes. Licensee shall be responsible for any and all
taxes that may be levied by a proper taxing authority on royalties or other payments accruing to Salk under this Agreement. Such taxes may not be deducted from royalties or other payments to be paid to Salk hereunder. Licensee acknowledges 

  

 18 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
that Salk, as a not-for-profit corporation, does not qualify under U.S. tax laws for a tax credit on any taxes paid by Licensee. 
 8.5 Late Payments. Late payments shall be subject to a charge of one and one-half percent (1.5%) per month compounded, or the maximum amount
allowed by applicable law, whichever is lower. The payment of such late charges shall not prevent Salk from exercising any other rights it may have as a consequence of the lateness of any payment. 
  

	9	TERM AND TERMINATION. 

 9.1 Term. Unless earlier terminated under this Section 9, this Agreement shall begin on the Effective Date and expire on the date of expiration or abandonment of the last to expire or be abandoned of any
patent included in the Patent Rights. 
 9.2 Termination.  
 (a) Termination by Licensee. Licensee may initiate termination of this Agreement by giving written notice to Salk. Sixty
(60) days after such notice and upon Licensee fulfilling the below obligations, the License will be deemed terminated. 
 (ii) Licensee shall pay all amounts due to Salk under this Agreement through the termination date; and 
 (iii) Licensee shall submit a report of the type described in Section 8.1; and 
 (iv) Licensee
shall return any materials, samples, documents, and information, which embody or disclose Patent Rights provided to Licensee by Salk in connection with this Agreement 
 (b) Termination By Salk. Salk has the right to terminate this Agreement as follows: 
 (i) If Licensee does not make a payment due hereunder and fails to cure such non-payment (including the payment of interest in
accordance with Section 8.5) within thirty (30) days after the date of notice in writing of Licensee’s failure to meet a payment obligation; 
  

 19 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 (ii) If Licensee defaults in its indemnification and insurance obligations under
Section 6 and fails to cure such default within thirty (30) days after the date of notice in writing; 
 (iii) If, at any time, Licensee does not meet the diligence requirements pursuant to Section 12, and fails to cure such default within thirty (30) days after the date of notice in writing; 
 (iv) If Licensee knowingly attempts to use, sublicense, transfer or assign its rights or obligations under this Agreement in any
manner contrary to the terms of this Agreement or in derogation of Salk’s proprietary rights. 
 (v) If Licensee
fails to provide reports (progress reports, royalty reports) or copies of sublicense agreements and fails to cure such deficits within thirty (30) days after the date of notice in writing of such deficit by Salk; 
 (vi) If an examination by an independent accountant pursuant to Section 8.2 shows an underreporting or underpayment by
Licensee in excess of twenty percent (20%) for any twelve (12) month period, and Licensee fails to cure such underreporting or underpayment within thirty (30) days after the date of notice in writing; 
 (vii) If Licensee is convicted of a felony relating to the manufacture, use or sale of Licensed Products or Biological Materials;
or 
 (viii) Except as provided in subparagraphs (i)—(vii) above, if Licensee defaults in the performance of any
obligations under this Agreement and the default has not been remedied within sixty (60) days after the date of notice in writing of such default by Salk. The failure of Salk to exercise its rights of termination shall not be deemed to be a
waiver of any right Salk might have, nor shall such failure preclude Salk from exercising or enforcing said right upon any subsequent failure by Licensee. 
 (c) Termination for Breach. Either Party shall have the right to terminate this Agreement if the other party materially breaches or defaults in the performance of any obligations under 

  

 20 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
this Agreement (in such capacity, the “Breaching Party”) and the default has not (i) been remedied within sixty (60) days after receipt
of notice in writing specifying such breach or default, or (ii) if such breach is not susceptible to cure within sixty (60) days of the receipt of written notice of the breach, the Breaching Party is diligently pursuing a cure and both
parties have mutually agreed on a time for cure in excess of sixty (60) days. The failure of a party to exercise its rights of termination shall not be deemed to be a waiver of any right that party might have, nor shall such failure preclude
Salk from exercising or enforcing said right upon any subsequent failure by Licensee. 
 (c) Termination for
Insolvency. Except to the extent prohibited by law, either party may, at its option and without notice, terminate this Agreement, effective immediately, if the other party: (i) admits in writing its inability to pay its debts generally as
they become due; (ii) is adjudicated by a court of competent jurisdiction as being insolvent; (iii) has a decree entered against it by a court of competent jurisdiction appointing a receiver, liquidator, trustee, or assignee in insolvency
covering all or substantially all of such party’s property (which appointment is not vacated within sixty (60) days of the entry of the order of appointment) or providing for the liquidation of such party’s property or business
affairs; (iv) makes an assignment for the benefit of creditors; or (v) shall have a petition in bankruptcy filed for or against it (which is not dismissed within sixty (60) days of the petition). 
 9.3 Consequences of Expiration or Termination. 
 (a) In the event of expiration of this Agreement or termination of the Agreement for any reason whatsoever: 
 (i) Licensee shall not thereby be discharged from any liability or obligation to Salk that became due or payable prior to the effective date of such expiration or termination. 
 (ii) The rights and obligations of the parties under Sections 5, 6, 7, 8.2, 9.3, 10, 11, and 14 shall survive any expiration or
termination of this Agreement. 
 (iii) Licensee shall promptly return all documents, information, and other materials
received from Salk which embody or disclose Patent Rights. 
  

 21 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 (iv) All sublicenses shall survive to the extent provided in Section 2.2. All
payments then or thereafter due to Licensee from each surviving sublicense shall become owed directly to Salk; provided that, Salk shall remit to Licensee the amount by which any such payments exceed the corresponding amount that would have been
payable by Licensee to Salk hereunder. 
 (b) In the event of termination of the Agreement: 
 (i) If Licensee, its Affiliates or its Sublicensees then possess Licensed Product, have started the manufacture thereof or have
accepted orders therefor, Licensee, its Affiliates or its Sublicensees shall have the right, for up to one hundred eighty (180) days following the date of termination, to sell their inventories thereof, complete the manufacture thereof and
market such fully manufactured Licensed Product, in order to fulfill such accepted orders, subject to the obligation of Licensee to pay Salk the royalty payments therefor as provided in Section 3 of this Agreement; 
 (ii) Subject to Section 9.3(b)(i), Licensee shall discontinue and shall cause its Affiliates to discontinue, the manufacture,
use, marketing, offering for sale and sale of Licensed Products. 
 (iii) Licensee shall provide a final report of the
type described in Section 8.1, including any allowable post-termination sales. 
  

	10	CONFIDENTIAL INFORMATION. 

 (a) The term “Confidential Information” means all confidential scientific, technical, financial, or business information furnished by a party (the “Disclosing Party”) to the
other party (the “Receiving Party”) in connection with this Agreement, including, without limitation, information contained in patent applications and Licensee’s business and financial information. Confidential Information that
is disclosed in writing shall be marked with the legend “CONFIDENTIAL” or similar legend. Confidential Information that is disclosed orally or visually shall be documented in a written notice prepared by the Disclosing Party and delivered
to the Receiving Party within thirty (30) days of the date of disclosure. Such notice shall summarize the Confidential Information disclosed to the Receiving Party and reference the time and place of disclosure. 
  

 22 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 (b) The Receiving Party shall and shall cause its employees engaged in the
performance of this Agreement to (i) maintain all Confidential Information in strict confidence, (ii) use Confidential Information only for the purposes of this Agreement, and (iii) not disclose Confidential Information to a third
party, except that the Receiving Party may disclose or permit the disclosure of any Confidential Information to its directors, officers, employees, and agents who are obligated to maintain the confidential nature of such Confidential Information and
who need to know such Confidential Information to perform tasks under this Agreement. 
 (c) The obligations with
respect to Confidential Information shall not apply to Confidential Information to the extent that a party can demonstrate by competent written evidence: (i) was in the public domain at the time of disclosure hereunder, (ii) later became
part of the public domain after the time of its disclosure hereunder through no act or omission of the Receiving Party, its employees agents, successors, or assigns, (iii) was lawfully disclosed to the Receiving Party at any time by a third
party having the right to disclose it, (iv) was already known by the Receiving Party at the time of disclosure or is independently developed or discovered by the Receiving Party without resort to such Confidential Information, (v) is
required to be disclosed by Receiving Party to a governmental agency pursuant to such agency’s rule and regulations in order to secure regulatory approval for a Licensed Product, provided that Licensee shall first give notice to Salk of such
disclosure and shall have made a reasonable effort to maintain the confidentiality of such information, or (vi) is required to be disclosed to comply with applicable laws or regulations, or with a court or administrative order, provided that
the Disclosing Party receives, to the extent practicable, prior written notice of such required disclosure and that the Receiving Party takes all reasonable and lawful actions to obtain confidential treatment for such disclosure and to minimize the
extent of such disclosure. Nothing contained herein shall prevent Licensee or its Affiliates from disclosing information to actual and prospective investors, Sublicensees, funding sources, merger partners and professional advisers in connection with
any such transaction so long as such disclosures are governed by these or substantially similar confidentiality provisions. 
  

 23 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

	11	CHOICE OF LAW; DISPUTE RESOLUTION. 

 11.1 Governing Law. This Agreement is made in accordance with and shall be governed and construed in accordance with the laws of the State of New
York, without regard to conflicts of laws rules. 
 11.2 Dispute Resolution. If a dispute arises between the parties relating to the
interpretation or performance of this Agreement or the grounds for the termination thereof, the parties agree to hold a meeting, attended by individuals with decision-making authority regarding the dispute, to attempt in good faith to negotiate a
resolution of the dispute prior to pursuing other available remedies. If the dispute remains unresolved forty-five (45) days after the first meeting for the purpose of dispute resolution, then each party shall have the right to pursue alternate
dispute resolution or other remedies legally available to resolve the dispute. In the case of such alternate dispute resolution or other legal remedies, the prevailing party will be entitled to receive from the other party its reasonable
attorneys’ fees and costs. If both parties receive judgment in any dollar amount, the court will determine the prevailing party, taking into consideration the merits of the claims asserted by each party, the amount of the judgment received by
each party and the relative equities between the parties. 
  

	12	COMMERCIALIZATION. 

 12.1 Commercial Development
Obligation. In order to maintain in force the license granted hereunder, Licensee shall use reasonable efforts and diligence to develop Licensed Products, as promptly as is reasonably and commercially feasible, and thereafter to produce and sell
reasonable quantities of Licensed Products. Mere sublicensing is not considered reasonable commercial efforts. The parties hereto acknowledge and agree that achievement of the milestones described in Section 12.2 shall be evidence of compliance
by Licensee with its commercial development obligations hereunder for the time periods specified in 12.2. In the event Salk, at any time, has a reasonable basis to believe that Licensee is not using reasonable efforts and diligence as required
hereunder, including failure to achieve the milestones described in Section 12.2, Salk shall provide Licensee with a notice that specifies the basis for such belief. Upon such notice, Licensee has sixty (60) days to respond in writing with
proof of diligence and/or a plan for cure to Salk’s satisfaction or Salk has the right to terminate the Agreement. 
 12.2 Diligence
Milestones. Prior to signing this Agreement, Licensee shall have provided to Salk the Commercial Development Plan attached hereto as Exhibit B, under which Licensee intends to 

  

 24 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
bring the subject matter of the Patent Rights to the point of commercial use. This Commercial Development Plan is hereby incorporated by reference into this
Agreement. 
 Licensee’s failure to perform its obligations under Exhibit B will be considered a material breach of this Agreement. Salk shall provide
Licensee with a notice that specifies the basis for such belief. Upon such notice, Licensee has thirty (30) days to respond in writing with proof of diligence and/or a plan for cure to Salk’s satisfaction or Salk has the right to terminate
the Agreement. 
 12.3 Progress Reports. Beginning on the first anniversary of the Effective Date and terminating on the date of first
Commercial Sale of a Licensed Product, Licensee shall provide to Salk on or before February 15 of each year a written report of its progress with respect to the scientific research and discovery, development, and commercialization of Licensed
Products. Such report shall include (i) identification of the Licensee, Affiliate or Sublicensee officers and employees having primary responsibility for developing such products, and (ii) the current status of and timetable for developing
such products including if applicable, plans for preclinical studies and estimated dates for initiation and completion of clinical trials, manufacturing, sublicensing, marketing and sales during the most recent twelve (12) month period and
plans for the forthcoming year. If actual progress differs from that anticipated in the Commercial Development Plan required under Section 12.2, Licensee shall provide to Salk a written explanation of the reasons for the difference and a
modified Commercial Development Plan. The modified Commercial Development Plan shall require Salk’s approval if it contains modified performance milestones unless such modifications are the result of changes required by the FDA in the scope or
extent of testing required for Licensed Products prior to first Commercial Sale. 
 12.4 U.S. Manufacture. To the extent necessary to
comply with US Government regulations for the licensing of federally funded inventions, Licensee, its Affiliates and any sublicensee(s) will commit, to the extent required by law, that Licensed Products sold in the US will be manufactured
substantially in the US. Notwithstanding the foregoing, if during the term of the License Agreement, Licensee, its Affiliates and/or its sublicensees can provide compelling evidence to Salk that such manufacture in the US would impose an
extraordinary burden on Licensee, its Affiliates or any sublicensee, Salk shall at that time agree to seek a waiver from the US Government with respect to the requirement that Licensed Products for sale in the US be manufactured substantially in the
US. Licensee 

  

 25 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
understands that Salk cannot guarantee that such waiver can be obtained. Licensee shall bear all costs associated with seeking such waiver. 
 12.5 Foreign Registration. Licensee agrees to register this Agreement with any foreign governmental agency that requires such registration, and
Licensee shall pay all costs and legal fees in connection therewith. In addition, Licensee shall assure that all foreign laws affecting Licensee’s performance under this Agreement or the sale of Licensed Products are fully satisfied.

  

	13	ADDRESSES. 

 Except as otherwise provided, payments
to be made hereunder to Salk shall be made by wiring the required amount to Salk’s bank in accordance with Salk’s instructions or by mailing or sending by commercial courier checks for the required amount to Salk’s address. Except as
otherwise provided, notices and reports provided for herein shall effectively be given by mailing the same by certified or registered mail or by delivery by commercial courier, in each case properly addressed to the other party with charges prepaid.
For the purposes of making payments and giving notices, the addresses of the parties hereto are as follows: 
 If to Salk: The Salk Institute
for Biological Studies 
 10010 North Torrey Pines Road 
 La Jolla, CA 92037 
 Attn: Licensing Administrator, Office of Technology Management 
 If to Licensee: Merrion Research II, Ltd. 
 3rd Floor Biotechnology Building 
 Trinity College, Dublin 2 Dublin IRELAND 
 Attn: Dr. Thomas Leonard, Director 
 or to such
subsequent addresses as either party may furnish the other by giving notice thereof as provided in this Section 13. 
  

 26 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

	14	MISCELLANEOUS. 

 14.1
Assignment. 
 (a) Licensee may assign this Agreement as part of: 
 (i) Sale, merger or other transfer of Licensee’s entire business; or 
 (ii) Sale or other transfer of that part of Licensee’s business to which the license granted hereby relates; or 
 (iii) A transaction other than described in (i) or (ii), following payment to Salk of a fee of [***]. 
 (b) Salk shall release Licensee of liability hereunder upon receipt of writing from successor or assignee expressly agreeing to be
bound by all the terms and provisions of this Agreement. 
 (c) Licensee shall notify Salk within ten (10) days of
any assignment of this Agreement by Licensee and provide the new contact information of assignee. 
 (d) Upon
assignment of this Agreement to a successor or assignee as provided under 14.1(a), the term “Licensee” as used herein shall mean such successor assignee. 
 (e) Salk may not assign or otherwise transfer this Agreement without the consent of Licensee. 
 14.2 Headings. The headings used in this Agreement are for convenience of reference only and are not intended to be a part of or to affect the
meaning or interpretation of this Agreement. 
 14.3 Amendment. No amendment or modification hereof shall be valid or binding upon the
parties unless made in writing and signed by both parties. 
 14.4 Bankruptcy. Licensee agrees to provide notice to Salk of its
intention to file a voluntary petition in bankruptcy or, where known to Licensee, of another party’s intention to file an involuntary petition in bankruptcy for Licensee, said notice to be received by Salk at least one hundred and twenty
(120) days prior to filing such voluntary petition. Salk may terminate this Agreement upon receipt of 

  

 27 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 
such notice at its sole discretion. Unless otherwise provided by law, Licensee’s failure to provide such notice to Salk will be deemed a material,
pre-petition, incurable breach of this Agreement and the Agreement will terminate automatically on the date of filing such voluntary or involuntary petition in bankruptcy. Notwithstanding the above, Licensee agrees to provide notice to Salk upon
filing a voluntary petition in bankruptcy. 
 14.5 Force Majeure. Any delays in performance by any party under this Agreement (other
than the payment of monies due) shall not be considered a breach of this Agreement if and to the extent caused by occurrences beyond the reasonable control of the party affected, including but not limited to: acts of god, embargoes, governmental
restrictions, strikes or other concerted acts of workers, fire, flood, explosion, riots, wars, civil disorder, rebellion or sabotage. The party suffering such occurrence shall immediately notify the other party and any time for performance hereunder
shall be extended by the actual time of delay caused by the occurrence. 
 14.6 Independent Contractors. In making and performing this
Agreement, Salk and Licensee act and shall act at all times as independent contractors and nothing contained in this Agreement shall be construed or implied to create an agency, partnership or employer and employee relationship between Salk and
Licensee. At no time shall one party make commitments or incur any charges or expenses for or in the name of the other party except as specifically provided herein. 
 14.7 Use of Salk’s Name. Except as otherwise provided herein or required by law, Licensee will not originate any publication, news release or other public announcement, written or oral, whether in the
public press or otherwise, relating to this Agreement or to the performance hereunder, without the prior written approval of Salk, which approval will not be unreasonably withheld. Such planned publication, news release or other public announcement
shall be provided five (5) days in advance for approval by Salk. Notwithstanding the foregoing, Salk agrees that Licensee may make known in promotional and technical literature that the Patent Rights were developed at Salk by Dr. Jean E.F.
Rivier and other scientists in his/her laboratory and that products are offered under license from Salk; provided, however, that such use shall not state or imply that Salk has any relationship with Licensee other than as licensor. 
  

 28 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 14.8 Publication. Licensee agrees that Salk (including its employees) shall have a right to
publish in accordance with its general policies, and that this Agreement shall not restrict, in any fashion, Salk’s right to publish, subject to Section 10 of this Agreement. 
 14.9 Severability. If any term, condition or provision of this Agreement is held to be unenforceable by a court having proper jurisdiction for any
reason, it shall, if possible, be interpreted rather than voided, in order to achieve the intent of the parties to this Agreement to the extent possible. In any event, all other terms, conditions and provisions of this Agreement shall be deemed
valid and enforceable to the full extent of the law. 
 14.10 Waiver. None of the terms, covenants, and conditions of this Agreement
can be waived except by the written consent of the party waiving compliance. Waiver of one term, covenant or condition, shall not be construed as waiver of any other term, covenant or condition. 
 14.11 Entire Agreement. This Agreement and Exhibits attached hereto contain the entire agreement and understanding between the parties with
respect to the subject matter hereof, and merges all prior discussions, representations and negotiations with respect to the subject matter of this Agreement. 
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement by their duly authorized officers or representatives. 
 SALK INSTITUTE FOR BIOLOGICAL STUDIES 
  

			
		
	By:	 	/s/ Anne-Marie Mueller
		 	Anne-Marie Mueller.
	Title:	 	Director, Office of Technology Management

  

 29 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

			
	MERRION RESEARCH I, LTD.
		
	By:	 	/s/ Thomas Leonard
		 	Dr. Thomas Leonard
	Title:	 	Director, Merrion Research

  

 30 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 EXHIBIT A 
 PATENT RIGHTS 
 U.S. Patent No. 5,506, 207, issued April 9, 1996,
entitled, “GnRH Antagonists XIII” 
  

 31 
 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY’S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

 EXHIBIT B 
 Licensee Commercial Development Plan 
  

			
	 Principal activities
	  	Quarter Initiated
	 Clinical trials supplies manufacturing for Phase I
	  	Q3/07
	 Phase I clinical trials
	  	Q4/07
	 Phase II clinical trials
	  	Q4/08
	 CTM for Phase III
	  	Q2/09
	 Phase III Clinical Trials (2 studies)
	  	Q4/09
	 NDA submission
	  	Q1/12Option Agreement, dated December 15, 2005, Delcan Ryan

 Exhibit 10.10 
 DATED with effect from 10 April 2006 
 MERRION PHARMACEUTICALS LIMITED 
 DECLAN RYAN 
 OPTION DEED

 Deed of Agreement 
 (As
amended on 22 November 2006) 
 A & L GOODBODY 
 North Wall Quay 
 Dublin 1 

 THIS DEED is dated with effect from 10 April 2006 and made between: 
  

	 (A)
	 MERRION PHARMACEUTICALS LIMITED of 3rd Floor, Biotechnology Building, Trinity College, Dublin 2 (Company which expression shall include its successors) and 

  

	(B)	DECLAN RYAN c/o Irelandia II Limited, Research Building, National College of Ireland, Mayor Street, Dublin 1 (Grantee which expression shall include his successors and
assigns). 

 RECITALS 
 In connection with a
re-organisation of the Merrion Group, the Company has agreed to grant to the Grantee options to subscribe for shares and/or stock in the capital of the Company upon the terms and subject to the conditions set out in this Agreement. 
 IT IS HEREBY AGREED as follows:- 
  

	1.	INTERPRETATION 

  

	 	1.1.	In this Agreement, unless the context otherwise requires:- 

 the Act means the Taxes Consolidation Act, 1997 as amended; 
 Constitutional Documentation means the articles of
association of the Company from time to time; 
 connected shall have the same meaning as in section 26 of the Companies Act 1990;

 Control means having an interest in shares or stock in a body corporate conferring in aggregate over 50 per cent of the total
voting rights conferred by the entire issued capital or stock in the body corporate from time to time and conferring the right to vote at all general meetings of the body corporate and shall include shares in the body corporate held by connected
persons and Controlled shall be construed accordingly; 
 Deed of Adherence means a Deed of Adherence approved under the
Shareholders Agreement; 
 Equity Securities means for the time being voting shares or stock in the capital of the Company with rights
to participate in distributions both by way of dividend and on a winding up of the Company other than shares or stock which as respects dividends and/or capital carry a right to participate only up to a specified amount in a distribution;

 Fundraising means the first completed funding round of the Company after the date hereof under which the Company receives not less
than seven million five hundred thousand EURO (€7,500,000) in cash by way of subscription for Equity Securities or debt convertible into Equity Securities; 
 fully diluted basis means assuming that all rights to subscribe or otherwise acquire or call for the allotment of Equity Securities granted or agreed to be granted as at the date hereof have been exercised
(including for the avoidance of doubt and where the context so admits as to the exercise of the Option); 
 Guarantee means a guarantee
given by the Grantee to AIB Bank in connection with indebtedness of any Group Company; 
 Guarantee Payment Amount means such sums as
are owing under the agreed Finance Documents; 
  

 1 

 Guarantee Release Date means such date upon which AIB Bank confirm in writing to the Grantee that
no further sums are owing and no further liability or obligation exists on his part under the Guarantee; 
 Grantee Group means the
Grantee and for the time being any firm, person and/or body corporate controlled by the Grantee or holding any rights or entitlements hereunder on behalf of the Grantee. 
 Group Company means any one of the Company, its Subsidiaries, any Holding Company of the Company or any Subsidiary of its Holding Company, and any company or body corporate Controlled by a majority of the
members for the time being of the Company, and Group shall be construed accordingly (and for the avoidance of doubt the Company shall be deemed to be a body corporate for the purposes of section 155 of the Companies Act 1963); 
 Holding Company shall have the same meaning as “holding company” in section 155 of the Companies Act, 1963; 
 Option means an option to subscribe for the Option Shares at the Option Price at any time upon and subject to the terms of this Agreement;

 Option Exercise Notice means a notice given under clause 3.1; 
 Option Exercise Period means commencing on the date hereof and ending 365 days after a Fundraising; 
 Option Price means a price per Option Share derived from a valuation of the Group being the lower of (i) the pre-money valuation of the
Company upon which the last equity fundraising before the Fundraising was based and (ii) the pre-money valuation of the Company upon which the Fundraising is based; and if the Option is exercised in the absence of any proposed Fundraising, then
(i) shall be used as the basis of valuation of the Group; 
 Option Shares means such number of Equity Securities which, upon the
exercise of the Option, represents five per cent (5%) of the issued share capital of the Company on a fully diluted basis subject only to dilution to allow for the exercise by certain senior employees of the Group pursuant to their respective
Service Agreements (as defined in the Shareholders Agreement) and by Elan Corporation plc of rights to subscribe for Equity Securities as and to the extent set out or provided for in the Shareholders Agreement; 
 Shareholders Agreement means the shareholders agreement dated 10 April 2006 Growcorp (G.P) Limited (as general partner for and on behalf of
European Bioscience Fund I Limited Partnership), Growcorp Group Limited, Enterprise Ireland, Merrion Biopharma Limited, and the Company; 
 Subsidiary shall have the same meaning as “subsidiary” in section 155 of the Companies Act, 1963. 
  

	 	1.2.	Headings are inserted for convenience only and do not affect the construction of this Agreement. 

  

	 	1.3.	Unless the context otherwise requires, words importing the singular include the plural and vice versa, words importing the masculine include the feminine, and words importing
persons include corporations. Save as otherwise provided herein, references to clauses, paragraphs and Schedules are to those contained in this Agreement 

  

	 	1.4.	Unless the contrary is clearly stated, references to acts, statutory instruments and other legislation are to legislation operative in Ireland and to such legislation amended,
extended or re-enacted (whether before or after the date hereof) from time to time, and include any legislation of which it is a re-enactment (whether with or without modification) and also include any subordinate legislation made from time to time
under that legislation. 

  

 2 

	 	1.5.	Reference to any document includes that document as amended or supplemented from time to time. 

  

	 	1.6.	A document is in “the agreed form” if it is in the form of a draft agreed between and initialled by or on behalf of the parties hereto on or before the date hereof.

  

	 	1.7.	All references in this Agreement to costs, charges or expenses include any value added tax or similar tax charged or chargeable in respect thereof. 

  

	2.	GRANT OF OPTION 

  

	 	2.1.	In consideration of the sum of one hundred EURO (€100) paid by the Grantee to the Company (the receipt, adequacy and sufficiency of which is hereby acknowledged by the
Company), the Company hereby grants to the Grantee the Option to subscribe for the Option Shares at the Option Price free from all liens charges and encumbrances pursuant to the terms and conditions of this Agreement. 

  

	 	2.2.	The Company represents and warrants that: 

  

	 	2.2.1.	the entry into and performance by the Company of this Agreement has been duly and properly authorised and all consents, waivers and authorisations (whether by members of the Company
or any other parties) necessary or desirable in connection with each thereof have been obtained (including a waiver of any and all pre-emption rights howsoever described and wheresoever set out) and all acts, conditions and things required to be
obtained, done, fulfilled and performed in order (i) to enable the Company lawfully to enter into, exercise its rights under and perform and comply with the obligations expressed to be assumed by it in this Agreement; (ii) to ensure that
the obligations expressed to be assumed by it in this Agreement are legal, valid and binding, have been obtained, done, fulfilled and performed and the obligations expressed to be assumed by the Company in this Agreement are legal and valid
obligations binding on it in accordance with the terms thereof; 

  

	 	2.2.2.	as at the date hereof, no steps have been taken or, to the best of the knowledge, information and belief of the directors of the Company, are being taken to appoint a receiver,
liquidator or an examiner over any Group Company or any part of any Group Companys’ undertaking or assets, or to wind up any Group Company and each Group Company is able to pay its debts as they fall due; 

  

	 	2.2.3.	as at the date hereof, there is no material litigation or dispute existing, pending or to the best of the knowledge, information and belief of the directors of the Company,
threatened against any Group Company; 

  

	 	2.2.4.	Schedule 1 contains a true, up to date and correct copy of the Constitutional Documentation of the Company; and 

  

	 	2.2.5.	Schedule 2 contains a true, up to date and correct capitalisation table showing all Equity Securities and the holders thereof (or rights thereto) on a fully diluted basis and
all other stock and shares in the capital of the company. 

  

	 	2.3.	The Company agrees and undertakes not to do or permit any matter or thing to be done or undertaken the effect of which could reasonably be considered to frustrate or interfere with
the exercise by the Grantee of the Option in accordance with the terms of this Agreement. 

  

 3 

	3.	PROCEDURE ON EXERCISE OF THE OPTION AND SHAREHOLDER MATTERS 

  

	 	3.1.	The exercise of the Option by the Grantee shall be effected by giving written notice, served in accordance with the terms of this Agreement during the Option Exercise Period (after
which time the Option will cease to be exercisable). 

  

	 	3.2.	Within fourteen (14) days of the Option Exercise Notice being given, the Company will allot the Option Shares, shall issue a share certificate or electronic equivalent in
respect thereof to the Grantee (or, as he may direct, to his nominee) and shall deliver a Deed of Adherence (with counterparts) duly executed by all parties to the Shareholders Agreement upon receipt of which the Grantee shall duly execute and
deliver a Deed of Adherence (with counterparts) to the Company. Payment for the Option Shares shall be made in the manner set out in Clause 3.6. 

  

	 	3.3.	It is acknowledged by the Company that in any shareholders agreement to which the Grantee may be or become a party (whether the Shareholders Agreement, any amendment version thereof
and any replacement thereof), the Grantee shall be entitled to participate on a pro rata basis with and on terms no less favourable than those afforded to all other holders of Equity Securities, in all respects on a fully diluted basis, in respect
of rights and entitlements to information and reporting on and inspection rights in relation to the Company and each Group Company and pre-emption rights and co-sale rights (in each case howsoever described) in relation to the sale or allotment of
Equity Securities. 

  

	 	3.4.	All Option Shares shall rank pari passu in all respects with all fully paid Equity Securities. 

  

	 	3.5.	The Company shall at all time keep available sufficient authorised but unissued share capital to enable the requisite Option Shares to be issued and allotted to the Grantee in
accordance with the terms of this Agreement. 

  

	 	3.6.	In the event that the Option is exercised: 

  

	 	3.6.1.	before the Guarantee Release Date, the Option Shares shall, pending the Guarantee Release Date, be issued nil paid but in all other respects with all rights attaching thereto and
exercisable in connection therewith as if fully paid. In that event, if on the Guarantee Release Date: 

  

	 	(a)	the aggregate Option Price in respect of the Option Shares exceeds the Guarantee Payment Amount, the amount of the Guarantee Payment Amount shall be set off first in deemed payment
up of the par value of the Option Shares and thereafter against the balance of the aggregate Option Price of the Option Shares then outstanding and any remaining balance of the aggregate Option Price of the Option Shares shall then be payable
forthwith to the Company by the Grantee; or 

  

	 	(b)	the Guarantee Payment Amount exceeds the aggregate Option Price in respect of the Option Shares, such amount of the Guarantee Payment Amount equal to the aggregate Option Price of
the Option Shares shall be set off first in deemed payment up of the par value of the Option Shares and thereafter against the balance of the aggregate Option Price of the Option Shares then outstanding and the balance of Guarantee Payment Amount
shall remain due and outstanding in accordance with its terms; 

  

	 	3.6.2.	after the Guarantee Release Date, then the Option Shares shall be issued credited as fully paid and 

  

	 	(a)	 if the aggregate Option Price in respect of the Option Shares exceeds the Guarantee Payment Amount, the amount of the 

  

 4 

	 	 
Guarantee Payment Amount shall be set off against the aggregate Option Price of the Option Shares then outstanding and any remaining balance of the aggregate
Option Price of the Option Shares shall then be payable forthwith to the Company by the Grantee; or 

  

	 	(b)	if the Guarantee Payment Amount exceeds the aggregate Option Price in respect of the Option Shares, such amount of the Guarantee Payment Amount equal to the aggregate Option Price
of the Option Shares shall be set off against the aggregate Option Price of the Option Shares and the balance of Guarantee Payment Amount shall remain due and outstanding in accordance with its terms. 

  

	 	3.6.3	the Grantee acknowledges that without prejudice to all other rights and entitlements to which he may be entitled under the Finance Documents, and for the avoidance of doubt, upon
and to the extent of the full, valid and effective occurrence of the matters set out in clauses 3.6.1 and 3.6.2 above, the amount of the Guarantee Payment Amount shall be reduced by the amount of such set off. 

  

	4.	ADJUSTMENTS IN THE EVENT OF AN ALTERATION IN THE STRUCTURE OF SHARE CAPITAL 

  

	 	4.1.	In the event of any alteration taking place in the capital structure of the Company whether by way of capitalisation of profits or reserves, consolidation or subdivision of shares,
the conversion of one class of shares to another, the reduction of capital, a spin off or similar occurrence, a declaration of a dividend payable in a form other than shares in an amount that has material effect on the market value of the Equity
Securities, the Grantee may, subject to the prior written consent of the Company adjust one or more of the following:- 

  

	 	4.1.1.	the definition of Option Share; 

  

	 	4.1.2.	the number of Option Shares in respect of which any Option may be exercised; 

  

	 	4.1.3.	the Option Price payable by the Grantee for Option Shares (save that such Option Price may not, in any circumstances, be higher than the Option Price determined by this Agreement);
and 

  

	 	4.1.4.	where the Option has been exercised but no Option Shares have been allotted pursuant thereto, the number of Option Shares which may be allotted; 

 so as to reflect such adjustment. 
  

	 	4.2.	Notwithstanding anything herein contained if the exercise by the Grantee of the Option would result in Option Shares being issued at a discount to nominal value, the Option Price
shall be increased to the aggregate nominal value of those Option Shares. 

  

	5.	MISCELLANEOUS 

  

	 	5.1.	Whole Agreement: This Agreement (including the documents and instruments referred to herein and therein) supersedes all prior representations, arrangements, understandings
and agreements between the parties relating to the subject matter hereof, and sets forth an entire, complete and exclusive agreement and understanding between the parties relating to the subject matter hereof. No parties may rely on any
representation, arrangement, understanding or agreement (whether written or oral) neither expressly set out or referred to in this Agreement. 

  

 5 

	 	5.2.	Variation: This Agreement may not be released, discharged, supplemented, amended, varied or modified in any manner except by an instrument in writing signed by the parties
herein, or by a duly authorised officer or representative or each of them. 

  

	 	5.3.	Forbearance and Waiver: No waiver by a party in respect of any breach will operate as a waiver in respect of any subsequent breach. No failure or delay by a party in
exercising any right or remedy will operate as a waiver thereof, nor will any single or partial exercise or waiver of any right or remedy prejudice its further exercise or the exercise of any other right or remedy. 

  

	 	5.4.	Notices: 

  

	 	5.4.1.	Any notice or other communication given or made under this agreement shall be in writing and may be delivered to the relevant party or sent by prepaid post, e-mail or facsimile to
the address of that party specified in this agreement or to that party’s facsimile number thereat or by e-mail to the e-mail address of that party specified in this agreement or such other address, e-mail address or number as may be notified
hereunder by that party from time to time for this purpose and will be effected notwithstanding any change of address, facsimile number, e-mail address not so notified. 

  

	 	5.4.2.	Unless the contrary is proved, each such notice or communication will be deemed to have been given or made and delivered, if by post 72 hours after posting, if by delivery when left
at the relevant address, if by facsimile upon transmission, subject to the code or facsimile number being received on the transmission report, if by e-mail upon transmission, subject to the confirmation of the e-mail transmission report.

  

	 	5.5.	No Assignment by Grantee: Subject as hereinafter provided, the Grantee may not assign or transfer any of his rights or obligations under this Agreement without the prior
written consent of the Company provided that the Grantee is permitted to assign and transfer its rights and obligations to a member of the Grantee Group and in the event that member of the Grantee Group ceasing to be a member of the Grantee Group it
shall first assign its rights and obligations hereunder to another member of the Grantee Group. 

  

	 	5.6.	Severance: All the terms and provisions of this Agreement are distinct and severable and if any term or provision is held to be unenforceable, illegal or void by a court it
shall to that extent be deemed not to form part of this Agreement and the enforceability, legality and validity of the remainder of this Agreement will not be affected. 

  

	 	5.7.	Governing Law and Jurisdiction: This Agreement and all relationships created hereby will in all respects be governed by and construed in accordance with Irish law. It is
hereby irrevocably agreed that the Irish courts are to have exclusive jurisdiction to settle any disputes which may arise under, out of or in connection with this Agreement or its performance and accordingly that any suit, action or proceeding shall
arise and shall be brought in such courts. 

  

 6 

 IN WITNESS whereof this Deed has been entered into the date and year first herein WRITTEN.

 GIVEN under 
 the common seal of 
 MERRION PHARMACEUTICALS LIMITED 
  

					
			
	 	 		 	/s/ John Lynch
		 		 	Director
			
	 	 		 	/s/ Jonathan O’Connell
		 		 	Director/Secretary
			
	SIGNED, SEALED and DELIVERED by	 		 	/s/ Declan Ryan
	 DECLAN RYAN
 In the presence of:
	 		 	

  

 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]